The α-BAFF-R antibody used for ADCC assays was provided by Novartis (Basel, Switzerland) and has been described previously. 13 To determine the percentage of NK cells in samples, cells were ...
In a phase II study, anti-BAFF therapy with belimumab was well-tolerated and had clear effects on B cells. 9 In a detailed analysis of peripheral blood B-cell subsets, belimumab induced dramatic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback